Open AccessThis article is
- freely available
Disease-Causing Allele-Specific Silencing by RNA Interference
National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, Japan
Received: 27 December 2012; in revised form: 28 March 2013 / Accepted: 2 April 2013 / Published: 11 April 2013
Abstract: Small double-stranded RNAs (dsRNAs) of approximately 21-nucleotides in size, referred to as small interfering RNA (siRNA) duplexes, can induce sequence-specific posttranscriptional gene silencing, or RNA interference (RNAi). Since chemically synthesized siRNA duplexes were found to induce RNAi in mammalian cells, RNAi has become a powerful reverse genetic tool for suppressing the expression of a gene of interest in mammals, including human, and its application has been expanding to various fields. Recent studies further suggest that synthetic siRNA duplexes have the potential for specifically inhibiting the expression of an allele of interest without suppressing the expression of other alleles, i.e., siRNA duplexes likely confer allele-specific silencing. Such gene silencing by RNAi is an advanced technique with very promising applications. In this review, I would like to discuss the potential utility of allele-specific silencing by RNAi as a therapeutic method for dominantly inherited diseases, and describe possible improvements in siRNA duplexes for enhancing their efficacy.
Keywords: RNAi; allele-specific silencing; siRNA selection; dominantly inherited disease; nucleotide variation; allele discrimination; siRNA modification; forked siRNA
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Hohjoh, H. Disease-Causing Allele-Specific Silencing by RNA Interference. Pharmaceuticals 2013, 6, 522-535.
Hohjoh H. Disease-Causing Allele-Specific Silencing by RNA Interference. Pharmaceuticals. 2013; 6(4):522-535.
Hohjoh, Hirohiko. 2013. "Disease-Causing Allele-Specific Silencing by RNA Interference." Pharmaceuticals 6, no. 4: 522-535.